FDA Approves Ozempic for Lowering Kidney Disease Risks in Adults With Diabetes

Ozempic is also approved for reducing the risk of heart-related death in diabetic patients with chronic kidney disease, the Danish drugmaker said.

The injectable drug Ozempic in an undated file photograph. David J. Phillip/AP Photo

Drugmaker Novo Nordisk said on Jan. 28 that the U.S. Food and Drug Administration (FDA) had approved Ozempic for lowering the risk of kidney failure and disease progression in adults with Type 2 diabetes.

The semaglutide medication is also approved for reducing the risk of death from cardiovascular disease in patients with Type 2 diabetes and chronic kidney disease, according to Novo Nordisk’s statement.